Marksans Pharma Limited (BOM:524404)
266.85
-0.25 (-0.09%)
At close: Jul 20, 2026
Marksans Pharma Revenue
In the fiscal year ending March 31, 2026, Marksans Pharma had annual revenue of 29.51B INR with 12.51% growth. Marksans Pharma had revenue of 8.56B in the quarter ending March 31, 2026, with 20.84% growth.
Revenue
29.51B
Revenue Growth
+12.51%
P/S Ratio
4.10
Revenue / Employee
16.04M
Employees
1,840
Market Cap
120.97B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 29.51B | 3.28B | 12.51% |
| Mar 31, 2025 | 26.23B | 4.45B | 20.46% |
| Mar 31, 2024 | 21.77B | 3.25B | 17.56% |
| Mar 31, 2023 | 18.52B | 3.61B | 24.23% |
| Mar 31, 2022 | 14.91B | 1.15B | 8.33% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 82.80B |
| Granules India | 53.66B |
| Viyash Scientific | 34.20B |
| AstraZeneca Pharma India | 22.76B |
| Caplin Point Laboratories | 21.87B |
| FDC Limited | 21.71B |
| Sanofi India | 17.74B |
| Rubicon Research | 17.54B |
Marksans Pharma News
- 13 days ago - Marksans Pharma to acquire ABCnow GmbH for €892,384 - Business Upturn
- 18 days ago - Marksans Pharma announces ₹0.90 per share final dividend for FY26 - Business Upturn
- 18 days ago - Marksans Pharma announces 90% final dividend ahead of AGM - Business Upturn
- 25 days ago - Marksans Pharma submits machine-readable financial results for March 2026 - Business Upturn
- 4 weeks ago - Marksans Pharma launches campaign to prevent transfer of unclaimed dividends - Business Upturn
- 5 weeks ago - Marksans Pharma completes acquisition of QliniQ B.V. - Business Upturn
- 7 weeks ago - Marksans Pharma launches 'Saksham Niveshak' campaign to address unclaimed dividends - Business Upturn
- 7 weeks ago - Marksans Pharma to acquire Netherlands-based QliniQ B.V. to expand presence in European markets - Business Upturn